RxDoctor Payments Data

Kevin Svancara, DO

MOHS-Micrographic Surgery · Goodyear, AZNPI 1083052872

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,890 of the $3,234 with a category attached, or 89.4%. 19 manufacturers reported payments, led by AbbVie at 30.0% of the total.

$3,234in general payments, 2019–2025

Across 149 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$970
  • Johnson & Johnson$591
  • Amgen$323
  • Regeneron Healthcare Solutions, Inc.$298
  • Galderma Laboratories, L.p.$221
  • Pfizer$161
  • plus $669 from 13 others

What the payments were for

  • Food & beverage$2,89089%
  • Education$34411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,234 in reported general payments places this provider in the 75th percentile of 38 mohs-micrographic surgery providers in Arizona.

See all mohs-micrographic surgery providers in Arizona

Medicare billing

Part B allowed, 2024
$804,535
Medicare patients
1,204
Services billed
8,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa16$338,305
OtezlaApremilast18$128,957
Cosentyx Sensoready (2 Pens)Secukinumab16$119,027
Dupixent PenDupilumab11$48,696
Fluorouracil149$10,163
Clobetasol Propionate169$6,063
Doxycycline Hyclate98$5,023
Metronidazole70$3,655
Triamcinolone Acetonide175$2,069
Ketoconazole135$2,028
Clindamycin Phosphate32$1,702
Acitretin11$1,392
Mupirocin95$863
Acetaminophen-CodeineAcetaminophen With Codeine230$765
Clotrimazole50$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$323$128,95718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 38 mohs-micrographic surgery providers in Arizona.

Other mohs-micrographic surgery in Goodyear

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →